Photocure

Photocure is a Norwegian pharmaceutical company that specializes in photodynamic therapy. The company's main product is Hexvix, a drug used in the diagnosis and management of bladder cancer.

History[edit | edit source]

Photocure was established in 1993 in Oslo, Norway. The company was founded with the aim of developing and commercializing new products and solutions for better patient care and health outcomes.

Photocure's flagship product, Hexvix, is a photosensitizing agent used in the diagnosis and management of bladder cancer. Hexvix is used in conjunction with blue light cystoscopy to enhance the detection of bladder cancer during surgical procedures.

The company also has a portfolio of other products including Cysview, Visonac, and Visonac cream, which are used in the treatment of various skin conditions.

Research and Development[edit | edit source]

Photocure invests heavily in research and development (R&D) to create innovative products and solutions. The company's R&D efforts are focused on the development of new drugs and therapies for the treatment of cancer and other diseases.

Financial Performance[edit | edit source]

Photocure's financial performance is driven by the sales of its products, particularly Hexvix. The company has a strong financial position, with steady revenue growth and a healthy profit margin.